Cargando…
Sustained release of a GLP-1 and FGF21 dual agonist from an injectable depot protects mice from obesity and hyperglycemia
There is great interest in identifying a glucagon-like peptide-1 (GLP-1)–based combination therapy that will more effectively promote weight loss in patients with type 2 diabetes. Fibroblast growth factor 21 (FGF21) is a compelling yet previously unexplored drug candidate to combine with GLP-1 due t...
Autores principales: | Gilroy, C. A., Capozzi, M. E., Varanko, A. K., Tong, J., D'Alessio, D. A., Campbell, J. E., Chilkoti, A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for the Advancement of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7449677/ https://www.ncbi.nlm.nih.gov/pubmed/32923621 http://dx.doi.org/10.1126/sciadv.aaz9890 |
Ejemplares similares
-
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
por: Willard, Francis S., et al.
Publicado: (2020) -
Use of a biomimetic hydrogel depot technology for sustained delivery of GLP-1 receptor agonists reduces burden of diabetes management
por: d’Aquino, Andrea I., et al.
Publicado: (2023) -
A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis
por: Pan, Qi, et al.
Publicado: (2021) -
Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction
por: Nauck, Michael A., et al.
Publicado: (2022) -
Is GLP‐1 a hormone: Whether and When?
por: D'Alessio, David
Publicado: (2016)